Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2001 Jul 28;323(7306):233.

Neomycin should not be used to treat hepatic encephalopathy

W H Curioso, K E Monkemuller
Comment

Neomycin should not be used to treat hepatic encephalopathy

W H Curioso et al. BMJ. .
No abstract available

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

Cited by

  • Managing complications in cirrhotic patients.
    Peck-Radosavljevic M, Angeli P, Cordoba J, Farges O, Valla D. Peck-Radosavljevic M, et al. United European Gastroenterol J. 2015 Feb;3(1):80-94. doi: 10.1177/2050640614560452. United European Gastroenterol J. 2015. PMID: 25653862 Free PMC article.

References

    1. Krige JE, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system: portal hypertension-2. Ascites, encephalopathy, and other conditions. BMJ. 2001;322:416–418. . (24 February.) - PMC - PubMed
    1. Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology. 1992;39:542–545. - PubMed
    1. Blanc P, Daures JP, Liautard J, Buttigieg R, Desprez D, Pageaux G, et al. Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial. Gastroenterol Clin Biol. 1994;18:1063–1068. - PubMed
    1. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol. 2000;12:203–208. - PubMed
    1. Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin. 1997;13:593–601. - PubMed

MeSH terms